Floatz logo

Catequentinib

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Rong TaoSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
Tucidinostat
Ruijin Hospital
Phase 4BB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Catequentinib is also rated in:

AnlotinibDormant
BB
Indicative ·
71 / 100
View asset →
refractory malignant neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →